BÖLÜM


DOI :10.26650/B/CH32.2024.010.014   IUP :10.26650/B/CH32.2024.010.014    Tam Metin (PDF)

Bi̇yoti̇ni̇daz Eksi̇kli̇ği̇ Olan Çocuğun İzlemi̇ ve Toplumda Bakımı

Meryem KaracaGülden Gökçay

Biyotinidaz eksikliği (BE) otozomal resesif kalıtılan bir geninin (BTD geni) sorumlu olduğu doğumsal metabolik bir hastalıktır. Tedavi edilmediği takdirde hipotoni, emme güçlüğü, ensefalopati, hipertoni, generalize ve miyoklonik nöbetler, infantil spazm, spastik paraparezi, ataksi, gelişme geriliği gibi nörolojik bulgular ile egzamatöz dermatit, alopesi gibi cilt bulguları görülebilir. Aynı zamanda optik atrofi, keratokonjuktivit, sensorinöral işitme kaybı, immünolojik bulgular ve laringeal stridor BE’nin diğer sistem bulgularıdır. BE 2008 yılından beri Ulusal Yenidoğan Tarama Programı ile ülkemizde taranmaktadır. Kesin tanı biyotinidaz enzim aktivitesi veya BTD geni analizi ile konulur. Biyotinidaz aktivitesi %10 altında ise belirgin BE, %10 -%30 arasında ise kısmi BE olarak adlandırılır. Tedavide oral biyotin kullanılmaktadır. Erken tanı ve tedavi ile yukarıda sayılan bulguların ortaya çıkması engellenebilir. Tedavi ömür boyudur. Otozomal resesif kalıtımı olan hastalıkta tanı alan bireyin ailesi de taranmalıdır. Her ne yaşta tanı konulursa konulsun, tanı alan bireye derhal tedavi başlanmalıdır ve ömür boyu tedaviye devam edilmelidir. Aile, hastalık hakkında ve tedavinin ömür boyu sürmesi gerektiği konusunda muhakkak bilgilendirilmelidir.


DOI :10.26650/B/CH32.2024.010.014   IUP :10.26650/B/CH32.2024.010.014    Tam Metin (PDF)

Follow-up and Community Care of the Child with Biotinidase Deficiency

Meryem KaracaGülden Gökçay

Biotinidase deficiency (BE) is an autosomal recessive inherited metabolic disease in which the BTD gene is responsible. If left untreated, symptoms include neurological findings such as hypotonia, difficulty in sucking, encephalopathy, hypertonia, generalized and myoclonic seizures, infantile spasm, spastic paraparesis, ataxia, and growth retardation; skin findings such as eczematous dermatitis and alopecia; and immunological findings such as optic atrophy, keratoconjunctivitis, sensorineural hearing loss, and laryngeal stridor. In Turkey, screening for BE has been available since 2008 under the National Newborn Screening Program. Definitive diagnosis is made by determining the biotinidase enzyme activity or BTD gene analysis. Profound BE is indicated if the biotinidase activity is below 10%, and partial BE, if it is between 10% and 30%. Early diagnosis and treatment with oral biotin can prevent BE symptoms. As treatment is a lifelong process, family members of the index case should also be screened and informed about BE. Regardless of the age at diagnosis, treatment should be immediately started and continued for life.  



Referanslar

  • 1. Leon-Del-Rfo A. Biotin-dependent regulation of gene expression in human cells. J Nutr Biochem. 2005 Jul;16(7):432-4. google scholar
  • 2. Tourbah A, Lebrun-Frenay C, Edan G, Clanet M, Papeix C, Vukusic S, et al. MD1003 (high-dose biotin) for the treatment of progressive multiple sclerosis: A randomised, double-blind, placebo-controlled study. Mult Scler. 2016;22(13):1719-31. google scholar
  • 3. Baumgartner MR, Suormala T. Biotin-responsive Disorders. In: Saudubray J-M, Baumgartner MR, Walter J, editors. Inborn Metabolic Diseases Diagnosis and Treatment. 6th Edition ed: Springer-Verlag Berlin Heidelberg; 2016;375-83. google scholar
  • 4. Wolf B, Grier RE, Allen RJ, Goodman SI, Kien CL. Biotinidase deficiency: the enzymatic defect in la-te-onset multiple carboxylase deficiency. Clin Chim Acta. 1983 Jul 15;131(3):273-81. google scholar
  • 5. Wolf B. Biotinidase Deficiency. 2000 Mar 24 [Updated 2016 Jun 9]. In: Adam MP, Everman DB, Mirzaa GM, et al., editors. GeneReviews® [Internet]. Seattle (WA): University of Washington, Seattle; 19932022. Erişim: from: https://www.ncbi.nlm.nih.gov/books/NBK1322/. Son erişim tarihi: 25.11.2022. google scholar
  • 6. Swango KL, Demirkol M, Hüner G, Pronicka E, Sykut-Cegielska J, Schulze A, et al. Partial biotinidase deficiency is usually due to the D444H mutation in the biotinidase gene. Hum Genet. 1998;102(5):571-5. google scholar
  • 7. Wolf B. Worldwide survey of neonatal screening for biotinidase deficiency. J Inherit Metab Dis. 1991;14(6):923-7. google scholar
  • 8. Baykal T, Hüner G, Sarbat G, Demirkol M. Incidence of biotinidase deficiency in Turkish newborns. Acta Paediatr. 1998;87(10):1102-3. google scholar
  • 9. Baykal T, Hüner G, Sarbat G, Demirkol M. The Cost-Benefit Evaluation Of Newborn Screening For Biotinidase Deficiency In Turkey. Med Bull lstanbul. 1999;32(2):170-3. google scholar
  • 10. Weber P, Scholl S, Baumgartner ER. Outcome in patients with profound biotinidase deficiency: relevance of newborn screening. Dev Med Child Neurol. 2004;46(7):481-4. google scholar
  • 11. Wolf B, Heard GS, Weissbecker KA, McVoy JR, Grier RE, Leshner RT, et al. Biotinidase deficiency: initial clinical features and rapid diagnosis. Ann Neurol. 1985;18(5):614-7. google scholar
  • 12. Wolf B. Biotinidase deficiency: “if you have to have an inherited metabolic disease, this is the one to have”. Genet Med. 2012;14(6):565-75. google scholar
  • 13. Ramaekers VT, Brab M, Rau G, Heimann G. Recovery from neurological deficits following biotin treat-ment in a biotinidase Km variant. Neuropediatrics. 1993;24(2):98-102. google scholar
  • 14. Bottin L, Prud’hon S, Guey S, Giannesini C, Wolf B, Pindolia K, et al. Biotinidase deficiency mimicking neuromyelitis optica: initially exhibiting symptoms in adulthood. Mult Scler. 2015;21:1604-7. google scholar
  • 15. Wolf B. Biotinidase deficiency should be considered in individuals exhibiting myelopathy with or without vision loss. Mol Genet Metab. 2015;116:113-8. google scholar
  • 16. Mardhiah M, Azize NAA, Yakob Y, Affandi O, Hock NL, Rowani MR, et al. Clinical, biochemical and mutational findings in biotinidase deficiency among Malaysian population. Mol Genet Metab Rep. 2020;22:100548. google scholar
  • 17. İş S. Yenidoğan Tarama ile Saptanan Biyotinidaz Eksikliği Vakalarının Değerlendirilmesi, Uzmanlık Tezi, İstanbul Üniversitesi, 2021. google scholar
  • 18. Zempleni J, Hassan YI, Wijeratne SS. Biotin and biotinidase deficiency, Expert Review of Endocrinology & Metabolism, 2008;3(6):715-24. google scholar
  • 19. Zengin PA, Ciki K, Mete Y, Ilter Bahadur E, Karahan S, Ozmert EN, et al. Developmental and behavioral outcomes of preschool-aged children with biotinidase deficiency identified by newborn screening. Euro-pean journal of pediatrics, 2021;180(1):217-24. google scholar


PAYLAŞ




İstanbul Üniversitesi Yayınları, uluslararası yayıncılık standartları ve etiğine uygun olarak, yüksek kalitede bilimsel dergi ve kitapların yayınlanmasıyla giderek artan bilimsel bilginin yayılmasına katkıda bulunmayı amaçlamaktadır. İstanbul Üniversitesi Yayınları açık erişimli, ticari olmayan, bilimsel yayıncılığı takip etmektedir.